The global glycosylated peptide market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030. The growth of this market is driven by the increasing prevalence of chronic diseases such as cancer and diabetes, which are associated with increased risk for developing complications such as cardiovascular disease and kidney failure.
The global glycosylated peptide market is segmented on the basis of type into monoclonal antibodies (MABs) and erythropoietin (EPO). MABs are used in oncology applications, while EPO is used in blood disorder applications. The application segment includes oncology and blood disorder applications. Oncology application accounted for the largest share in 2017 owing to its high prevalence among cancer patients globally, which has led to an increase in demand for MABs that can be used as a treatment option for these patients.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as diabetes and cancer are driving the growth of the Glycosylated Peptide market globally.
- The increasing demand for personalized medicine is also driving the growth of the Glycosylated Peptide market globally.
- Increasing research and development activities in this field are also contributing to the growth of this market.
- The introduction of new technologies such as nanotechnology, biotechnology, and proteomics will provide opportunities for new entrants in this field.
Industry Growth Insights published a new data on “Glycosylated Peptide Market”. The research report is titled “Glycosylated Peptide Market research by Types (Monoclonal Antibodies (MABs), Erythropoietin (EPO), Others), By Applications (Oncology, Blood Disorder, Others), By Players/Companies Sandoz International, Pfizer, Roche, Teva Pharmaceuticals Industries, Celltrion, Biocon, Dr.Reddys Laboratories, Medtronic, Cipla, Bachem Americas”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glycosylated Peptide Market Research Report
By Type
Monoclonal Antibodies (MABs), Erythropoietin (EPO), Others
By Application
Oncology, Blood Disorder, Others
By Companies
Sandoz International, Pfizer, Roche, Teva Pharmaceuticals Industries, Celltrion, Biocon, Dr.Reddys Laboratories, Medtronic, Cipla, Bachem Americas
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Glycosylated Peptide Market Report Segments:
The global Glycosylated Peptide market is segmented on the basis of:
Types
Monoclonal Antibodies (MABs), Erythropoietin (EPO), Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Blood Disorder, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sandoz International
- Pfizer
- Roche
- Teva Pharmaceuticals Industries
- Celltrion
- Biocon
- Dr.Reddys Laboratories
- Medtronic
- Cipla
- Bachem Americas
Highlights of The Glycosylated Peptide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies (MABs)
- Erythropoietin (EPO)
- Others
- By Application:
- Oncology
- Blood Disorder
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glycosylated Peptide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glycosylated peptides are peptides that have been chemically modified with a glycoside group. Glycosylation can occur naturally during the manufacturing process or it can be added later by a glycoprotein synthesis company. The addition of a glycoside group to a protein molecule alters its chemical properties, including its ability to interact with other proteins and cells in the body.
Some of the major players in the glycosylated peptide market are Sandoz International, Pfizer, Roche, Teva Pharmaceuticals Industries, Celltrion, Biocon, Dr.Reddys Laboratories, Medtronic, Cipla, Bachem Americas.
The glycosylated peptide market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glycosylated Peptide Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glycosylated Peptide Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glycosylated Peptide Market - Supply Chain
4.5. Global Glycosylated Peptide Market Forecast
4.5.1. Glycosylated Peptide Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glycosylated Peptide Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glycosylated Peptide Market Absolute $ Opportunity
5. Global Glycosylated Peptide Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glycosylated Peptide Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies (MABs)
5.3.2. Erythropoietin (EPO)
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glycosylated Peptide Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glycosylated Peptide Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Blood Disorder
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glycosylated Peptide Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glycosylated Peptide Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glycosylated Peptide Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glycosylated Peptide Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glycosylated Peptide Demand Share Forecast, 2019-2026
9. North America Glycosylated Peptide Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glycosylated Peptide Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glycosylated Peptide Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Blood Disorder
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glycosylated Peptide Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies (MABs)
9.7.2. Erythropoietin (EPO)
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glycosylated Peptide Demand Share Forecast, 2019-2026
10. Latin America Glycosylated Peptide Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glycosylated Peptide Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glycosylated Peptide Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Blood Disorder
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glycosylated Peptide Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies (MABs)
10.7.2. Erythropoietin (EPO)
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glycosylated Peptide Demand Share Forecast, 2019-2026
11. Europe Glycosylated Peptide Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glycosylated Peptide Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glycosylated Peptide Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Blood Disorder
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glycosylated Peptide Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies (MABs)
11.7.2. Erythropoietin (EPO)
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glycosylated Peptide Demand Share, 2019-2026
12. Asia Pacific Glycosylated Peptide Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glycosylated Peptide Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glycosylated Peptide Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Blood Disorder
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glycosylated Peptide Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies (MABs)
12.7.2. Erythropoietin (EPO)
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glycosylated Peptide Demand Share, 2019-2026
13. Middle East & Africa Glycosylated Peptide Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glycosylated Peptide Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glycosylated Peptide Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Blood Disorder
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glycosylated Peptide Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies (MABs)
13.7.2. Erythropoietin (EPO)
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glycosylated Peptide Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Glycosylated Peptide Market: Market Share Analysis
14.2. Glycosylated Peptide Distributors and Customers
14.3. Glycosylated Peptide Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sandoz International
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva Pharmaceuticals Industries
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Celltrion
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biocon
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Dr.Reddys Laboratories
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Medtronic
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Cipla
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bachem Americas
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
